Melanie Lee

Chief Scientific Officer

BTG

As CSO for BTG, Melanie Lee is a member of the BTG leadership team. She stepped off the Board of BTG plc in 2014 (after 4 years of service) to pursue this role to ensure R&D delivery for BTG and to build a product pipeline.

During her industrial career, Melanie has led R&D through many major mergers and integrations across the full range of company sizes from start-up to large pharma and with medical modalities spanning small molecules, biologic agents and devices. Within BTGplc the portfolio includes devices for loco-regional treatment of serious health conditions such as cancer, administered by specialist interventional physicians.

In addition to her role in BTG plc, Melanie is a Non-Executive Director of the Board of Sanofi.

Melanie’s academic grounding in molecular genetics involved three complex systems of DNA repair, & recombination and culminated in cell cycle repair and the demonstration of the existence of the human CDC2 gene being able to replace a yeast equivalent. This led to the linkage of pivotal areas of cell cycle research in eukaryotic systems with human cell cycle and cancer biology.

Since 1998, Melanie’s industrial career has been in research through Glaxo & GlaxoWellcome, leading R&D at Celltech/UCB, and as CEO of Syntaxin and NightstaRx.

Melanie became CEO of venture backed Syntaxin in 2010 which was sold to Ipsen in 2013 and she was founding CEO for NightstaRx, a Syncona, Wellcome Trust company in 2014. Melanie transitioned to the Board of NightstaRx at the end of 2014 to step down from the BTGplc Board and to take the current role of CSO for BTGplc.

Previous non-executive positions have included Deputy Chairman Cancer Research UK, Chairman CRT, NED of BTGplc, Lundbeck A/S and NightstaRx Ltd and she served as a Council Member for the Academy of Medical Sciences.

MELANIE LEE

Chief Scientific Officer

BTG

BIOGRAPHY

As CSO for BTG, Melanie Lee is a member of the BTG leadership team. She stepped off the Board of BTG plc in 2014 (after 4 years of service) to pursue this role to ensure R&D delivery for BTG and to build a product pipeline.

During her industrial career, Melanie has led R&D through many major mergers and integrations across the full range of company sizes from start-up to large pharma and with medical modalities spanning small molecules, biologic agents and devices. Within BTGplc the portfolio includes devices for loco-regional treatment of serious health conditions such as cancer, administered by specialist interventional physicians.

In addition to her role in BTG plc, Melanie is a Non-Executive Director of the Board of Sanofi.

Melanie’s academic grounding in molecular genetics involved three complex systems of DNA repair, & recombination and culminated in cell cycle repair and the demonstration of the existence of the human CDC2 gene being able to replace a yeast equivalent. This led to the linkage of pivotal areas of cell cycle research in eukaryotic systems with human cell cycle and cancer biology.

Since 1998, Melanie’s industrial career has been in research through Glaxo & GlaxoWellcome, leading R&D at Celltech/UCB, and as CEO of Syntaxin and NightstaRx.

Melanie became CEO of venture backed Syntaxin in 2010 which was sold to Ipsen in 2013 and she was founding CEO for NightstaRx, a Syncona, Wellcome Trust company in 2014. Melanie transitioned to the Board of NightstaRx at the end of 2014 to step down from the BTGplc Board and to take the current role of CSO for BTGplc.

Previous non-executive positions have included Deputy Chairman Cancer Research UK, Chairman CRT, NED of BTGplc, Lundbeck A/S and NightstaRx Ltd and she served as a Council Member for the Academy of Medical Sciences.